AffiliationDepartment of Pediatrics, Waterford Regional Hospital, Dunmore Road, Waterford,, Ireland.
MetadataShow full item record
CitationCochrane Database Syst Rev. 2010 Sep 8;(9):CD006388.
JournalCochrane database of systematic reviews (Online)
AbstractBACKGROUND: Routine care for chylothorax in neonate includes either conservative or surgical approaches. Octreotide, a somatostatin analogue, has been used for the management of patients with refractory chylothorax not responding to conservative management. OBJECTIVES: To assess the efficacy and safety of octreotide in the treatment of chylothorax in neonates. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), MEDLINE and EMBASE (to March 7, 2010). We assessed the reference lists of identified trials and abstracts from the annual meetings of the Pediatric Academic Societies published in Pediatric Research (2002 to 2009) without language restrictions. SELECTION CRITERIA: We planned to include randomised or quasi-randomised controlled trials of octreotide in the treatment of congenital or acquired chylothorax in term or preterm neonates, with any dose, duration or route of administration. DATA COLLECTION AND ANALYSIS: Data on primary (amount of fluid drainage, respiratory support, mortality) and secondary outcomes (side effects) were planned to be collected and analysed using mean difference, relative risk and risk difference with 95% confidence intervals. MAIN RESULTS: No randomised controlled trials were identified. Nineteen case reports of 20 neonates with chylothorax in whom octreotide was used either subcutaneously or intravenously were identified. Fourteen case reports described successful use (resolution of chylothorax), four reported failure (no resolution) and one reported equivocal results following use of octreotide. The timing of initiation, dose, duration and frequency of doses varied markedly. Gastrointestinal intolerance and clinical presentations suggestive of necrotizing enterocolitis and transient hypothyroidism were reported as side effects. AUTHORS' CONCLUSIONS: No practice recommendation can be made based on the evidence identified in this review. A prospective registry of chylothorax patients and a subsequent multicenter randomised controlled trial are needed to assess the safety and efficacy of octreotide in the treatment of chylothorax in neonates.
- Octreotide for congenital and acquired chylothorax in newborns: A systematic review.
- Authors: Bellini C, Cabano R, De Angelis LC, Bellini T, Calevo MG, Gandullia P, Ramenghi LA
- Issue date: 2018 Aug
- Octreotide Use in Neonates: A Case Series.
- Authors: Zaki SA, Krishnamurthy MB, Malhotra A
- Issue date: 2018 Sep
- Somatostatin or octreotide as treatment options for chylothorax in young children: a systematic review.
- Authors: Roehr CC, Jung A, Proquitté H, Blankenstein O, Hammer H, Lakhoo K, Wauer RR
- Issue date: 2006 May
- Octreotide as therapeutic option for congenital idiopathic chylothorax: a case series.
- Authors: Shah D, Sinn JK
- Issue date: 2012 Apr
- Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants.
- Authors: Ohlsson A, Aher SM
- Issue date: 2006 Jul 19